The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with potential resistance to existing drugs emphasizes the need for new therapeutic modalities with broad variant activity. Here we show that ensovibep, a trispecific DARPin (designed ankyrin repeat protein) clinical candidate, can engage the three units of the spike protein trimer of SARS-CoV-2 and inhibit ACE2 binding with high potency, as revealed by cryo-electron microscopy analysis. The cooperative binding together with the complementarity of the three DARPin modules enable ensovibep to inhibit frequent SARS-CoV-2 variants, including Omicron sublineages BA.1 and BA.2. In Roborovski dwarf hamsters infected with SARS-CoV-2, ensovibep reduced fatality similarly to a standard-of-care monoclonal antibody (mAb) cocktail. When used as a single agent in viral passaging experiments in vitro, ensovibep reduced the emergence of escape mutations in a similar fashion to the same mAb cocktail. These results support further clinical evaluation of ensovibep as a broad variant alternative to existing targeted therapies for Coronavirus Disease 2019 (COVID-19).
Phage therapy of ventilator-associated pneumonia (VAP) is of great interest due to the rising incidence of multidrug-resistant bacterial pathogens. However, natural or therapy-induced immunity against therapeutic phages remains a potential concern. In this study, we investigated the innate and adaptive immune responses to two different phage cocktails targeting either Pseudomonas aeruginosa or Escherichia coli—two VAP-associated pathogens—in naïve mice without the confounding effects of a bacterial infection. Active or UV-inactivated phage cocktails or buffers were injected intraperitoneally daily for 7 days in C57BL/6J wild-type mice. Blood cell analysis, flow cytometry analysis, assessment of phage distribution and histopathological analysis of spleens were performed at 6 h, 10 days and 21 days after treatment start. Phages reached the lungs and although the phage cocktails were slightly immunogenic, phage injections were well tolerated without obvious adverse effects. No signs of activation of innate or adaptive immune cells were observed; however, both active phage cocktails elicited a minimal humoral response with secretion of phage-specific antibodies. Our findings show that even repetitive injections lead only to a minimal innate and adaptive immune response in naïve mice and suggest that systemic phage treatment is thus potentially suitable for treating bacterial lung infections.
15 March 2026 in Journal of Histochemistry & Cytochemistry
The chloride channel regulator, calcium-activated-1, CLCA1, acts as a multifunctional secreted glycoprotein in anion channel modulation, mucus homeostasis, immune regulation, and other functions. So far, it has been described in goblet and other mucus-producing cells in mucous membranes, primarily of the respiratory, alimentary, and urogenital tracts. Here, we identify the expression of CLCA1 in fibroblast-like synoviocytes and superficial as well as, to a lesser extent, intermediate zone chondrocytes of diarthrodial articular joints. The expression pattern was found to be conserved in major joints in mice, pigs, and humans. First analyses of degenerate or infectious inflammatory joint conditions in mice or pigs, respectively, suggest rather continuous expression levels in articular disease. We speculate that CLCA1 may be involved in articular anion conductance, proteoglycan homeostasis, and inflammation of articular joints, possibly similar to analogous functions of this molecule as established in mucous membranes of the lungs and intestine: